The effects of bortezomib on the ovariectomy applied rat uterus: A histopathological, stereological and immunohistochemical study

Khoshvaghti, Habib; Altunkaynak, Berrin Zuhal

doi:10.22038/ijbms.2018.24756.6152

Home Articles List Article Information

|
|
|
How to cite
RIS EndNote BibTeX APA MLA Harvard Vancouver
|
Share

Iranian Journal of Basic Medical Sciences

Articles in Press

Current Issue

Journal Archive

Volume 22 (2019)

Volume 21 (2018)

Issue 12

Issue 11

Issue 10

Issue 9

Issue 8

Issue 7

Issue 6

Issue 5

Issue 4

Issue 3

Issue 2

Issue 1

Volume 20 (2017)

Volume 19 (2016)

Volume 18 (2015)

Volume 17 (2014)

Volume 16 (2013)

Volume 15 (2012)

Volume 14 (2011)

Volume 13 (2010)

Volume 12 (2009)

Volume 11 (2008)

Volume 10 (2007)

Iranian Journal of Basic Medical Sciences
Rejection Rate	74%
Average time to first decision (days)	26.25

The effects of bortezomib on the ovariectomy applied rat uterus: A histopathological, stereological and immunohistochemical study

Article 4, Volume 21, Issue 11, November 2018, Page 1118-1125 PDF (1393 K)

Document Type: Original Article

DOI: 10.22038/ijbms.2018.24756.6152

Authors

Habib Khoshvaghti

¹; Berrin Zuhal Altunkaynak²

¹Department of Histology and Embryology, Medical Faculty, Bülent Ecevit University, Zonguldak, Turkey

²Department of Histology and Embryology, Medical Faculty, İstanbul Okan University, İstanbul, Turkey

Abstract

Objective(s): In this study, potential protective effects of Bortezomib (Bort), as a proteasome inhibitor, were investigated on the uterus of ovariectomized rats by histological, morphometric and immunohistochemical methods.
Materials and Methods: In this study, 18 Sprague dawley strain female rats (12 weeks old, 250-300 g body weight) were used. Animals in the control group (Cont, n=6) were not exposed to any treatment. Ovariectomy was performed on the experimental groups. They (n=12) were divided into ovariectomy (Ovt, n=6) and Bortezomib (Bort, n=6) subgroups. Twelve weeks later, the rats were perfused. Then, uterine tissues were removed and examined by morphometrical, and light and electron microscopy methods. In addition, immunoreactivity of nuclear factor-kappa (NF-κB) was evaluated.
Results: Morphometric and histopathological evaluations showed that Bort was effective in the uterus and protects the layer structures and the cells.
Conclusion: In the light of these findings, we suggest that for proteasome inhibitor particularly Bort is thought to be useful through proteasome inhibition and NF-κB pathway.

Keywords

Bortezomib Microscopy Ovariectomy Rat Stereology; Uterus

Main Subjects

Anatomical Sciences

References

1. Finch CE, Morgan DG. RNA and protein metabolism in the aging brain. Annu Rev Neurosci 1990; 13:75-88.
2. Hutter E, Renner K, Pfister G, Stockl P, Jansen-Durr P, Gnaiger E. Senescence-associated changes in respiration and oxidative phosphorylation in primary human fibroblasts. Biochem J 2004; 380:919-928.
3. Passos JF, Saretzki G, Ahmed S, Nelson G, Richter T, Peters H, et al. Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol 2007; 5:110-123.
4. Zwerschke W, Mazurek S, Stockl P, Hutter E, Eigenbrodt E, Jansen-Durr P. Metabolic analysis of senescent human fibroblasts reveals a role for AMP in cellular senescence. Biochem J 2003; 376:403-411.
5. Cuervo AM, Dice JF. When lysosomes get old. Exp Gerontol 2000; 35:119-131.
6. Perichon R, Bourre J. Aging-related decrease in liver peroxisomal fatty acid oxidation in control and clofibrate-treated mice. A biochemical study and mechanistic approach. Mech Ageing Dev 1996; 87:115-126.
7. Popper H. Aging and the liver. Prog Liver Dis 1986; 8:659-683.
8. Masters CJ, Crane DI. On the role of the peroxisome in ontogeny, ageing and degenerative disease. Mech Ageing Dev 1995; 80:69-83.
9. Foster HA, Bridger JM. The genome and the nucleus: a marriage made by evolution. Genome organisation and nuclear architecture. Chromosoma 2005; 114:212-229.
10. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001; 21:245-273.
11. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107:241-246.
12. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kappaB activation: From bench to bedside. Exp Biol Med 2008; 233:21-31.
13. Panwalkar A, Verstovsek S, Giles F. Nuclear Factor-KappaB modulation as a therapeutic approach in hematologic malignancies. Cancer 2004; 100:1578-1589.
14. Lawrence T. The Nuclear Factor NF-κB Pathway in Inflammation. Cold Spring Harb Perspect Biol 2009; 1: a001651.
15. Barmparas G, Branco BC, Schnuriger B, Lam L, Inaba K, Demetriades D. The incidence and risk factors of post-laparotomy adhesive small bowel obstruction. J Gastrointest Surg 2010; 14:1619-1628.
16. Castelo-Branco C, Palacios S, Combalia J, Ferrer M, Traveria G. Risk of hypoactive sexual desire disorder and associated factors in a cohort of oophorectomized women. Climacteric 2009; 12:525-532.
17. Hayes MG, Urbanek M, Ehrmann DA, Armstrong LL, Lee JY, Sisk R, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun 2015; 6:7502.
18. Parker WH, Broder MS, Liu ZM, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Clin Obstet Gynecol 2007; 50:354-361.
19. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008; 70:200-209.
20. Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int 2008; 14:111-116.
21. Dou QP, Zonder JA. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets 2014; 14:517-536.
22. Hilt W, Wolf DH. Proteasomes: Destruction as a programme. Trends Biochem Sci 1996; 21:96-102.
23. Kumatori A, Tanaka K, Inamura N, Sone S, Ogura T, Matsumoto T, et al. Abnormally high expression of proteasomes in human leukemic-cells. Proc Natl Acad Sci U S A 1990; 87:7071-7075.
24. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade™(Bortezomib). Cancer Invest 2004; 22:304-311.
25. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000; 6:3719-3728.
26. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62:4996-5000.
27. MacLaren AP, Chapman RS, Wyllie AH, Watson CJ. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 2001; 8: 210-218.
28. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82:110-122.
29. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-2622.
30. Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND. 150. Ann Oncol 2007; 18:116-121.
31. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
32. Richardson PG, Chanan-Khan A, Lonial S, Krishnan A, Carroll M, Alsina M, et al. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: Results of a phase 1/2 study. Br J Haematol 2011; 153:729-740.
33. Altunkaynak BZ, Önger ME, Altunkaynak ME, Ayranci E, Canan S. Brief introduction to stereology and sampling strategies: basic concepts of stereology. NeuroQuantology 2012; 10:31-43.
34. Altunkaynak BZ, Unal D, Altunkaynak ME, Halici Z, Kalkan Y, Keles ON, et al. Effects of diabetes and ovariectomy on rat hippocampus (a biochemical and stereological study). Gynecol Endocrinol 2012; 28:228-233.
35. Kalaycioglu A, Ucuncu Y, Altunkaynak BZ, Altunkaynak ME, Gundogdu C, Keles ON, et al. Stereological evaluation of the kidneys of anencephalic and normal fetuses. Ren Fail 2013; 35:110-117.
36. Dursun H, Albayrak F, Uyanik A, Keleş NO, Beyzagül P, Bayram E, et al. Effects of hypertension and ovariectomy on rat hepatocytes. Are amlodipine and lacidipine protective? (A stereological and histological study). TURK J Gastroenterol 2010; 21:387-395.
37. Driscoll JJ, Woodle ES. Targeting the ubiquitin+proteasome system in solid tumors. Semin Hematol 2012; 49:277-283.
38. Conrad C, Podolsky MJ, Cusack JC. Antiproteasomal agents in rectal cancer. Anticancer Drugs 2011; 22:341-350.
39. Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 2005; 11:5526-5533.
40. Veschini L, Belloni D, Foglieni C, Cangi MG, Ferrarini M, Caligaris-Cappio F, et al. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 2007; 109:2565-2570.
41. Sorollaa A, Yeramiana A, Vallsb J, Dolceta X, Bergadàa L, Llombart-Cussacc A, et al. Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. Mol Oncol 2012; 6:530-541.
42. Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M, et al. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol 2010; 150:428-437.
43. Unsal F, Sonmez MF. The effects of ovariectomy on ghrelin expression in the rat uterus. Adv Clin Exp Med 2014; 23:363-370.
44. Carbonel AAF, Baracat MCP, Simoes RS, Simoes MJ, Baracat EC, Soares JM. The soybean concentrated extract proliferates the vagina of adult rats. Menopause 2011; 18:93-101.
45. Fawcett DW, Deane HW. The effect of cortisone on uterine growth in ovariectomized rats receiving estradiol. Q J Microsc Sci 1951; 92:385-392.
46. Cevik O, Akpinar H, Oba R, Cilingir OT, Ozdemir ZN, Cetinel S, Yoldemir T. The effect of Momordica charantia intake on the estrogen receptors ESRα/ESRβ gene levels and apoptosis on uterine tissue in ovariectomy rats. Mol Biol Rep. 2015; 42: 167-177.
47. Rovillain E, Mansfield L, Caetano C, Alvarez-Fernandez M, Caballero OL, Medema RH, et al. Activation of nuclear factor-kappa B signalling promotes cellular senescence. Oncogene 2011; 30:2356-2366.
48. Adler AS, Sinha S, Kawahara TL, Zhang JY, Segal E, Chang HY. Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes Dev 2007; 21:3244-3257.
49. Cullen S, Ponnappan U, Ponnappan S. Proteasome inhibition up-regulates inflammatory gene transcription induced by an atypical pathway of NF-κB activation. Biochem Pharmacol 2010; 79:706-714.

Statistics

Article View: 177

PDF Download: 152